Lumiata, an AI-powered predictive analytics platform for managing healthcare costs, completed $14 million in Series B funding, led by Defy.vc and AllegisNL Capital along with existing investors Khosla Ventures and Blue Venture Fund.
The company will use the funding to scale its enterprise-grade AI platform and invest in customer acquisition and success.
Lumiata’s suite of products includes – predictive applications for healthcare business teams to manage underwriting and clinical costs and risks for improved decision support, transparency, and patient centricity. Lumiata’s machine learning toolkit is purpose-built for healthcare data scientists to build and deploy predictive models with speed and ease. Lumiata’s automated data management, pre-built models, and AutoML capabilities provide a low- or no-code option for healthcare organizations with limited data science expertise.
“Lumiata is breaking new ground in the adoption of AI across healthcare’s core functions of underwriting, cost management, and more individualized patient care. We relaunched Lumiata two years ago with a mission to democratize AI to reduce the cost of care and improve outcomes. We have an even greater purpose to realize this mission as COVID-19 changed healthcare and our world forever,” said Lumiata CEO Dilawar Syed.
“We will accelerate our investment in product, customers, and people to grow and scale the business.”
Image by Peggy und Marco Lachmann-Anke from Pixabay